Who owns Aclaris Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ACRS from SEC Form 13F filings across 167 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 167 institutions disclosed 138.5M shares of Aclaris Therapeutics, Inc. worth $727.3M — about 92.7% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
167
13F holders
$727.3M
value, 2026 filers
92.7%
of shares outstanding (138.5M sh)
40
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of ACRS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 12.7M | $66.9M | 0.7% | 8.5% | 0.0% |
| 2 | BML Capital Management, LLC | 11.0M | $57.6M | 30.7% | 7.3% | -8.5% |
| 3 | BlackRock, Inc. | 10.4M | $54.6M | 0.0% | 6.9% | +3.4% |
| 4 | Deep Track Capital, LP | 9.3M | $49.2M | 0.8% | 6.3% | 0.0% |
| 5 | Frazier Life Sciences Management, L.P. | 8.7M | $45.9M | 1.1% | 5.8% | +77.2% |
| 6 | FMR LLC | 7.0M | $37.1M | 0.0% | 4.7% | +2145.7% |
| 7 | Vivo Capital, LLC | 6.7M | $35.2M | 3.9% | 4.5% | 0.0% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 5.9M | $30.8M | 0.0% | 3.9% | +0.8% |
| 9 | MPM BIOIMPACT LLC | 5.2M | $27.2M | 2.0% | 3.5% | +396.7% |
| 10 | Decheng Capital LLC | 4.0M | $21.3M | 3.1% | 2.7% | 0.0% |
| 11 | Rock Springs Capital Management LP | 3.8M | $19.9M | 1.1% | 2.5% | -12.5% |
| 12 | STATE STREET CORP | 3.7M | $19.4M | 0.0% | 2.5% | +13.5% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 3.6M | $18.9M | 0.0% | 2.4% | +12.4% |
| 14 | Jones Hill Capital LP | 2.5M | $13.2M | 2.2% | 1.7% | +42.4% |
| 15 | STEMPOINT CAPITAL LPNEW | 2.1M | $10.8M | 1.9% | 1.4% | new |
| 16 | Siren, L.L.C.NEW | 2.0M | $10.7M | 0.3% | 1.4% | new |
| 17 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.9M | $9.8M | 0.0% | 1.3% | -54.0% |
| 18 | Kalehua Capital Management LLC | 1.8M | $9.6M | 7.3% | 1.2% | 0.0% |
| 19 | CITADEL ADVISORS LLC | 1.8M | $9.3M | 0.0% | 1.2% | +0.8% |
| 20 | BRAIDWELL LP | 1.8M | $9.2M | 0.4% | 1.2% | -18.1% |
| 21 | Cormorant Asset Management, LPNEW | 1.8M | $9.2M | 0.6% | 1.2% | new |
| 22 | PANAGORA ASSET MANAGEMENT INC | 1.5M | $7.8M | 0.0% | 1% | +9.1% |
| 23 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.4M | $7.5M | 0.0% | 1% | -3.0% |
| 24 | Balyasny Asset Management L.P. | 1.4M | $7.4M | 0.0% | 0.9% | -30.3% |
| 25 | ACADIAN ASSET MANAGEMENT LLC | 1.4M | $7.1M | 0.0% | 0.9% | -17.5% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.